Display Settings:

Format

Send to:

Choose Destination
    Ann N Y Acad Sci. 2011 Feb;1218:47-54. doi: 10.1111/j.1749-6632.2010.05771.x. Epub 2010 Sep 28.

    Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.

    Source

    Department of Endocrinology, Fleury Group, Brazil. ana.hoff@fleury.com.br

    Abstract

    Osteonecrosis of the jaw (ONJ), previously an entity associated with radiation therapy to the head and neck, has been observed in patients treated with bisphosphonates. Patients with metastatic breast cancer and myelomatous bone disease, commonly treated with high-potency nitrogen-containing bisphosphonates for a prolonged period of time, have the greatest risk of ONJ development. The reported frequency of ONJ ranges from 0.6% to 6.2% in breast cancer and from 1.7% to 15% in patients with multiple myeloma. Osteonecrosis of the jaw has also been observed in patients with other cancers such as prostate cancer and in benign bone disorders such as osteoporosis and Paget's disease in which the incidence is low. Risk factors associated with the development of ONJ include dental extractions, length of bisphosphonate treatment, and the type of bisphosphonate used. In this review, we summarize the reported incidence and risk factors associated with ONJ.

    © 2010 New York Academy of Sciences.

    PMID:
    20946574
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Blackwell Publishing

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk